Ipratropium Adultes Aguettant (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic (M3) receptors on airway smooth muscle, preventing acetylcholine‑induced bronchoconstriction. This competitive antagonism leads to relaxation of the bronchial muscles, widening the airways and facilitating better airflow in obstructive lung conditions.

The dosage of Ipratropium Adultes Aguettant is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. The prescriber will specify the number of inhalations and frequency according to approved guidelines.

Safety data for ipratropium bromide in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and under medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, providing the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details and any necessary import documentation.

Ipratropium is an anticholinergic bronchodilator, whereas beta‑agonists (e.g., albuterol) act on adrenergic receptors. Ipratropium provides a complementary mechanism, often used as add‑on therapy to beta‑agonists for enhanced bronchodilation, especially in patients with COPD who may not respond fully to beta‑agonists alone.

The product should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, direct sunlight, and heat sources. Ensure the inhalation device is sealed until use to maintain product integrity.

Ipratropium Adultes Aguettant is delivered via inhalation using a nebulizer or metered‑dose inhaler, as directed by the healthcare professional. The patient inhales the prescribed number of puffs or nebulized dose, typically spaced according to the prescribed schedule.

Serious risks include paradoxical bronchospasm, which can worsen breathing, and rare allergic reactions such as angioedema or anaphylaxis. Patients should be monitored for sudden respiratory distress, facial swelling, or severe skin reactions and seek immediate medical attention if these occur.

Patients with known hypersensitivity to ipratropium bromide, atropine, or any component of the formulation should avoid this product. Caution is also advised for individuals with narrow‑angle glaucoma, urinary retention, or severe prostatic hypertrophy, as anticholinergic effects may exacerbate these conditions.